Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fel d 1 is the primary allergen produced by domestic cats, responsible for the majority of allergic reactions in humans sensitive to cats. It is a tetrameric glycoprotein found in sebaceous, salivary, and anal glands, as well as fur and skin. It elicits strong IgE-mediated immune responses upon exposure, leading to symptoms ranging from mild rhinoconjunctivitis to severe asthma attacks. Therapeutic strategies target Fel d 1 to desensitize patients or modulate immune responses.
Hypoallergenic variants, peptide-based immunotherapy containing T-cell epitopes from Fel d 1, recombinant constructs coupled with immunomodulatory proteins, anti-Fel d 1 antibody-containing egg products
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fel d 1 allergen (cat) (None).